{"id":24307,"date":"2026-03-03T21:30:12","date_gmt":"2026-03-03T21:30:12","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/24307\/"},"modified":"2026-03-03T21:30:12","modified_gmt":"2026-03-03T21:30:12","slug":"roche-advances-in-weight-loss-market-amid-global-health-developments","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/24307\/","title":{"rendered":"Roche Advances in Weight Loss Market Amid Global Health Developments"},"content":{"rendered":"<p>&#13;<\/p>\n<p>Swiss pharmaceutical giant Roche sets its sights on dominating the weight-loss sector, seeking to rival Denmark&#8217;s Novo Nordisk. CEO Thomas Schinecker expressed ambitions to position Roche among the market&#8217;s top three, according to Handelsblatt&#8217;s report.<\/p>\n<p>Meanwhile, Aspen Pharmacare from South Africa predicts a return to double-digit profit growth by 2026 despite a recent earnings slump, while notable global health developments continue to unfold. Guinea and the U.S. entered a five-year health agreement, emphasizing collaborative efforts in advancing healthcare initiatives.<\/p>\n<p>In regulatory affairs, CMS plans to suspend enrollments in Elevance&#8217;s Medicare plans due to compliance issues, causing stock impacts. Simultaneously, the U.S. Food and Drug Administration reignites Intellia&#8217;s gene therapy trial after safety approval, while Cigna announces a significant CEO transition with veteran Brian Evanko stepping up.<\/p>\n<p>&#13;<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; Swiss pharmaceutical giant Roche sets its sights on dominating the weight-loss sector, seeking to rival Denmark&#8217;s Novo&hellip;\n","protected":false},"author":2,"featured_media":24308,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[15390,15388,212,1002,9219,15389,304,134,1904],"class_list":["post-24307","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-autism","tag-elevance","tag-gene-therapy","tag-health","tag-market-share","tag-medicare","tag-pharmaceutical","tag-roche","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116167378518690111","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/24307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=24307"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/24307\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/24308"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=24307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=24307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=24307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}